MedTrace Logo

Endostar for Locally Recurrent Nasopharyngeal Carcinoma

NCT02636231 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 96

Last updated 2021-02-03

No results posted yet for this study

Summary

The purpose of this study is to determine whether endostar and IMRT is effective in the treatment of locally recurrent nasopharyngeal carcinoma patients compared with IMRT alone.

Conditions

  • Nasopharyngeal Carcinoma

Interventions

DRUG

Endostatins

Endostar (Endostatins) is to give from the first day of IMRT, 201mg, civ d1-14, q3w for two cycles.

RADIATION

IMRT

IMRT is to give GTV 60Gy in 27 fractions.

Sponsors & Collaborators

  • JiangXi Province Tumor Hospital

    collaborator UNKNOWN

  • The First Affiliated Hospital of Clinical Medicine of G.D.P.U.

    collaborator UNKNOWN

  • Second Affiliated Hospital of Nanchang University

    collaborator OTHER

  • First People's Hospital of Foshan

    collaborator OTHER

  • Affiliated Cancer Hospital & Institute of Guangzhou Medical University

    collaborator OTHER

  • The Affiliated Ganzhou Hospital of Nanchang University

    collaborator OTHER

  • First Affiliated Hospital of Gannan Medical University

    collaborator OTHER

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Fei Han, M.D., Ph.D. · China: Ethics Committee

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2020-03-31
Completion
2021-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02636231 on ClinicalTrials.gov